TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Estimates

TriSalus Life Sciences (NASDAQ:TLSI) issued its quarterly earnings results on Thursday. The company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16), FiscalAI reports. The business had revenue of $11.41 million for the quarter, compared to analyst estimates of $10.27 million.

Here are the key takeaways from TriSalus Life Sciences’ conference call:

• Q2 revenue reached $11.4 million, up sequentially and 1.7% year over year, while gross margin improved to 86.8% from 83.9% due to lower unit costs and manufacturing improvements.
• CMS issued a new G-code extending TriNav reimbursement into physician office-based labs, broadening access beyond hospitals and ambulatory surgery centers and potentially supporting adoption in liver, uterine, prostate, and genicular embolization.
• TriSalus has 11 active clinical studies across 27 sites involving more than 400 treated patients; additional trials are launching in the second half of 2026, while PETER data has been submitted for peer-reviewed publication and TriNav Advance remains under FDA review.
• Management reiterated 2026 revenue guidance of $54 million to $57 million, representing 19%–26% growth, and expects sequential growth acceleration in the second half as the expanded sales force becomes more productive and first-half expansion costs decline.
• The commercial build-out increased sales and marketing expenses to $11.4 million from $7.2 million, contributing to a wider adjusted EBITDA loss of $7.1 million versus $5.3 million a year earlier, although management said its $46.3 million cash balance funds the strategic plan.

TriSalus Life Sciences Trading Up 15.2%

TriSalus Life Sciences stock traded up $0.74 during mid-day trading on Friday, hitting $5.61. The stock had a trading volume of 700,814 shares, compared to its average volume of 195,434. TriSalus Life Sciences has a 12 month low of $2.20 and a 12 month high of $7.95. The stock has a 50-day simple moving average of $4.17 and a two-hundred day simple moving average of $4.31. The company has a current ratio of 5.78, a quick ratio of 5.46 and a debt-to-equity ratio of 2.58. The stock has a market capitalization of $344.57 million, a PE ratio of -4.32 and a beta of 0.43.

Insider Activity at TriSalus Life Sciences

In related news, Director Michael P. Stansky bought 200,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $2.50 per share, with a total value of $500,000.00. Following the purchase, the director owned 399,698 shares in the company, valued at approximately $999,245. This trade represents a 100.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mats Wahlstrom bought 60,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average price of $2.53 per share, with a total value of $151,800.00. Following the acquisition, the director directly owned 147,555 shares of the company’s stock, valued at $373,314.15. The trade was a 68.53% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 719,682 shares of company stock worth $1,804,176. 16.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. acquired a new position in TriSalus Life Sciences in the 1st quarter valued at $187,000. Geode Capital Management LLC lifted its position in shares of TriSalus Life Sciences by 107.4% during the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock worth $2,480,000 after buying an additional 235,627 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TriSalus Life Sciences during the 2nd quarter worth $47,000. 2.58% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Weiss Ratings cut shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Lake Street Capital lowered their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Hold” and a consensus target price of $7.50.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.